NCT07260812招募中1 期
A Phase I Clinical Study on the Safety, Tolerability, and Efficacy of KSV01 Injection in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
TCRx Therapeutics Co.Ltd1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2025年9月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Dose-limiting Toxicity
研究概览
简要总结
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KSV01 Injection for patients with diffuse large B-cell lymphoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients or their legal guardians voluntarily participate in the study and provide written informed consent.
- •Aged 18 to 80 years (inclusive), male or female.
- •ECOG performance status score of ≤
- •Life expectancy > 3 months.
- •KPS score ≥
- •Patients with diffuse large B-cell lymphoma (DLBCL) diagnosed according to the 2016 WHO classification. Patients with DLBCL should have been diagnosed as relapsed or refractory after at least one prior line of systemic therapy.
- •CD19 positivity confirmed by flow cytometry and/or histopathology.
- •According to the Lugano 2014 criteria, the presence of PET-positive target lesions for tumor assessment is required (Deauville 5-Point Scale [5-PS] ≥ 4).
- •Adequate organ function.
- •Female patients of childbearing potential must have a negative urine/blood pregnancy test during the screening period and agree to use effective contraception for at least 1 year after infusion; male subjects with partners of childbearing potential must agree to use effective barrier contraception for at least 1 year after infusion.
排除标准
- •History of another primary malignancy that has not been in continuous remission for at least 2 years, except for the following conditions which are exempt from the 2-year limit: non-melanoma skin cancer, Stage I solid tumors treated with curative intent and low risk of recurrence, cured localized prostate cancer, biopsy-confirmed carcinoma in situ of the cervix, or squamous intraepithelial lesion identified on Pap smear.
- •Uncontrolled infectious disease within 4 weeks prior to enrollment.
- •Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
- •HIV infection.
- •Positive for Treponema pallidum(syphilis).
- •Severe autoimmune disease or immunodeficiency, with the exception of well-controlled Type I diabetes and thyroid disorders.
- •History of severe allergy or hypersensitivity to macromolecular biologic agents (e.g., antibodies, cytokines).
- •Participation in any other clinical trial within 4 weeks prior to enrollment.
- •History of clinically significant central nervous system (CNS) diseases, including but not limited to epilepsy, paresis, aphasia, stroke, severe head injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome.
- •Presence of isolated CNS involvement by lymphoma, or any ongoing CNS condition that precludes accurate neurological evaluation.
- •History of severe cardiovascular conditions within the past 6 months.
- •Presence of psychiatric illness.
- •History of drug abuse or addiction.
- •Use of the following medications or therapies:
- •Corticosteroids (physiologic replacement doses, and topical or inhaled steroids are permitted).
- •Chemotherapy.
- •GvHD Therapy.
- •Allogeneic hematopoietic stem cell transplantation.
- •Gene therapy.
- •Women who are breastfeeding.
- •In the investigator's judgment, the subject is unlikely to complete all protocol-required study visits or procedures (including follow-up visits) or unlikely to comply with the requirements for participation in this study.
研究组 & 干预措施
KSV01 Injection
Experimental
KSV01 Injection is one kind of third-generation non-replicative self-inactivating lentivirus vector which carries CD19 CAR.
干预措施: KSV01 Injection (Drug)
结局指标
主要结局
Dose-limiting Toxicity
时间窗: 28 days after administration
DLT evaluation period: The DLT evaluation period is defined as within 28 days (inclusive) after the subjects' first administration of KSV01 injection during the dose escalation stage. All adverse events should be graded and evaluated in accordance with CTCAE v5.0. Among them, cytokine release syndrome (CRS) and immune effector cell-related neurotoxicity syndrome (ICANS) should be determined and graded in accordance with the standards of the American Society for Transplantation and Cell Therapy (ASTCT).
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid TumorsColorectal CancerNon-Small Cell Lung CancerNCT07261631Novartis Pharmaceuticals180
招募中
1 期
A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal SprayNCT07259538VivaVision Biotech, Inc60
招募中
1 期
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor PatientsNCT07260305Kangabio AUSTRALIA LTD PTY57
招募中
3 期
A Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus BSC versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk MDS2022-500479-29-00Celgene Corp.166
招募中
1 期
Evaluation of the Safety, Tolerability and Pharmacokinetics of HY6725 in Healthy Adult ParticipantsNCT07262281Newsoara Biopharma Co., Ltd.74